老虎证券

BRIEF-Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDA

Reuters
2024-11-22
BRIEF-Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDA

Nov 22 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O:

  • LEXICON TO REPOSITION AS CLINICAL DEVELOPMENT-FOCUSED COMPANY FOLLOWING REGULATORY UPDATE FROM FDA

  • LEXICON PHARMACEUTICALS INC: EFFORTS EXPECTED TO REDUCE 2025 OPERATING COSTS BY $100 MILLION

  • LEXICON PHARMACEUTICALS INC: PRIORITIZING STRONG RESEARCH AND DEVELOPMENT PIPELINE INCLUDING ONGOING STUDIES IN DPNP, HCM AND OBESITY

  • LEXICON PHARMACEUTICALS INC: IMPLEMENTING STRATEGIC RESTRUCTURING TO ELIMINATE COMMERCIAL ORGANIZATION AND RATIONALIZE OPERATIONS ACROSS ALL FUNCTIONS

  • LEXICON PHARMACEUTICALS INC: TOTAL REDUCTION OF APPROXIMATELY 60 PERCENT OF EMPLOYEES, EFFECTIVE FOR MOST AFFECTED EMPLOYEES BY DECEMBER 31

  • LEXICON PHARMACEUTICALS INC: ELIMINATION OF PROMOTIONAL EFFORTS FOR INPEFA, PLANNED COMMERCIAL ACTIVITIES FOR ZYNQUISTA

  • LEXICON PHARMACEUTICALS INC: RECEIPT OF A "DEFICIENCIES PRECLUDE DISCUSSION" LETTER FROM FDA REGARDING NDA FOR ZYNQUISTA

Source text: ID:nGNXnl2zP

Further company coverage: LXRX.O

((Reuters.Briefs@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10